EE04391B1 - Kiirlahustuvate efavirenskapslite või -tablettideformulatsioonid, kasutades superlagundeid, ning nende valmistamise meetodid - Google Patents

Kiirlahustuvate efavirenskapslite või -tablettideformulatsioonid, kasutades superlagundeid, ning nende valmistamise meetodid

Info

Publication number
EE04391B1
EE04391B1 EEP200000589A EEP200000589A EE04391B1 EE 04391 B1 EE04391 B1 EE 04391B1 EE P200000589 A EEP200000589 A EE P200000589A EE P200000589 A EEP200000589 A EE P200000589A EE 04391 B1 EE04391 B1 EE 04391B1
Authority
EE
Estonia
Prior art keywords
superlaggregates
tablets
formulations
making
methods
Prior art date
Application number
EEP200000589A
Other languages
English (en)
Inventor
T. Makooi-Morehead William
D. Buehler John
R. Landmann Brian
Original Assignee
Dupont Pharmaceuticals Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22160544&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE04391(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dupont Pharmaceuticals Company filed Critical Dupont Pharmaceuticals Company
Publication of EE200000589A publication Critical patent/EE200000589A/et
Publication of EE04391B1 publication Critical patent/EE04391B1/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EEP200000589A 1998-04-07 1999-04-01 Kiirlahustuvate efavirenskapslite või -tablettideformulatsioonid, kasutades superlagundeid, ning nende valmistamise meetodid EE04391B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8092598P 1998-04-07 1998-04-07
PCT/US1999/007228 WO1999051239A1 (en) 1998-04-07 1999-04-01 Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants

Publications (2)

Publication Number Publication Date
EE200000589A EE200000589A (et) 2002-04-15
EE04391B1 true EE04391B1 (et) 2004-12-15

Family

ID=22160544

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000589A EE04391B1 (et) 1998-04-07 1999-04-01 Kiirlahustuvate efavirenskapslite või -tablettideformulatsioonid, kasutades superlagundeid, ning nende valmistamise meetodid

Country Status (27)

Country Link
US (2) US6238695B1 (et)
EP (1) EP1067936B1 (et)
JP (1) JP2002510634A (et)
KR (1) KR100634253B1 (et)
CN (1) CN1146419C (et)
AR (1) AR019031A1 (et)
AT (1) ATE223719T1 (et)
AU (1) AU756422B2 (et)
BR (1) BR9908810A (et)
CA (1) CA2321523C (et)
CZ (1) CZ300850B6 (et)
DE (1) DE69902893T2 (et)
DK (1) DK1067936T3 (et)
EA (1) EA003217B1 (et)
EE (1) EE04391B1 (et)
ES (1) ES2181417T3 (et)
HU (1) HU228498B1 (et)
IL (1) IL138078A (et)
NO (1) NO325824B1 (et)
NZ (1) NZ507566A (et)
PL (1) PL194309B1 (et)
PT (1) PT1067936E (et)
SK (1) SK284655B6 (et)
TW (1) TW576741B (et)
UA (1) UA72207C2 (et)
WO (1) WO1999051239A1 (et)
ZA (1) ZA200004313B (et)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA72207C2 (uk) * 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення
EP1332757B1 (en) * 1998-05-27 2012-06-13 Merck Sharp & Dohme Corp. Efavirenz compressed tablet formulation
US20010014352A1 (en) 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
EP1083885B1 (en) * 1998-06-11 2006-12-27 Pharmacia & Upjohn Company LLC Delavirdine tablet formulation
US7037524B2 (en) * 2001-10-03 2006-05-02 Herbalscience, Llc Oral delivery of a botanical
US7291352B2 (en) 2001-10-03 2007-11-06 Herbalscience Llc Methods and compositions for oral delivery of Areca and mate' or theobromine
US20050053678A1 (en) * 2001-10-03 2005-03-10 Gow Robert T. Methods and compositions for betel nut chewing gum
US20050069596A1 (en) * 2001-10-03 2005-03-31 Gow Robert T. Compositions and methods comprising kava and anti-anxiety compounds
US20030124186A1 (en) * 2001-11-27 2003-07-03 Hussain Munir A. Efavirenz tablet formulation having unique biopharmaceutical characteristics
FR2834212B1 (fr) * 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
US20050037025A1 (en) * 2002-10-03 2005-02-17 Gow Robert T. Methods and compositions comprising kava and mate' or theobromine
KR20090053867A (ko) 2003-01-14 2009-05-27 길리애드 사이언시즈, 인코포레이티드 복합 항바이러스 치료를 위한 조성물 및 방법
WO2006020962A2 (en) 2004-08-13 2006-02-23 Gallipot, Inc. Palatable suspending vehicle for pharmaceutical ingredients
US20060099253A1 (en) * 2004-10-20 2006-05-11 Wyeth Antibiotic product formulation
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
CN101272848B (zh) * 2005-07-28 2013-03-13 Isp投资有限公司 改进喷雾干燥的粉末和颗粒材料性质的方法，以及由此生产的产品
WO2007013047A2 (en) * 2005-07-29 2007-02-01 Ranbaxy Laboratories Limited Water-dispersible anti-retroviral pharmaceutical compositions
AP2008004533A0 (en) * 2005-12-14 2008-08-31 Cipla Ltd Pharmaceutical combination
EP2043613A1 (en) * 2006-07-14 2009-04-08 Fmc Corporation Solid form
MX2009002873A (es) * 2006-09-14 2009-05-19 Chemlink Lab Llc Metodo para preparar formas de dosis solida que forman una pasta, crema o gel cuando se diluyen para uso final.
WO2008076780A2 (en) * 2006-12-14 2008-06-26 Isp Investments Inc. Amorphous valsartan and the production thereof
WO2008080037A2 (en) * 2006-12-21 2008-07-03 Isp Investments Inc. Carotenoids of enhanced bioavailability
JP5508859B2 (ja) * 2007-01-26 2014-06-04 アイエスピー インヴェストメンツ インコーポレイテッド 噴霧乾燥製品を製造するための調剤処理方法
US20080181961A1 (en) * 2007-01-26 2008-07-31 Isp Investments, Inc. Amorphous oxcarbazepine and the production thereof
US20080311162A1 (en) * 2007-05-16 2008-12-18 Olivia Darmuzey Solid form
EP2076248A2 (en) * 2007-08-17 2009-07-08 Teva Pharmaceutical Industries Ltd. Methods and compositions for controlling the bioavailability of poorly soluble drugs
WO2010008719A2 (en) * 2008-06-16 2010-01-21 Schering Corporation Oral pharmaceutical formulations of vla-4 antagonists
WO2010125572A1 (en) * 2009-04-29 2010-11-04 Hetero Research Foundation Compressed tablets and capsules containing efavirenz
ES2969969T3 (es) 2010-01-27 2024-05-23 Viiv Healthcare Co Combinaciones de dolutegravir y lamivudina para el tratamiento de la infección por VIH
NZ602955A (en) * 2010-04-20 2015-02-27 Cipla Ltd Pharmaceutical composition comprising efavirenz
EP2579892A2 (en) 2010-06-09 2013-04-17 Vaccine Technologies, Incorporated Therapeutic immunization in hiv infected subjects receiving stable antiretroviral treatment
CN102872019A (zh) * 2012-09-17 2013-01-16 北京阜康仁生物制药科技有限公司 一种采用微粉化技术的依非韦伦制剂
WO2015059466A1 (en) 2013-10-25 2015-04-30 Cipla Limited Pharmaceutical compositions comprising efavirenz
PE20180690A1 (es) 2015-04-27 2018-04-23 Intercept Pharmaceuticals Inc Composiciones de acido obeticolico y metodos de uso
EP3334419A1 (en) 2015-08-14 2018-06-20 Sandoz AG Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz
CN114404377B (zh) * 2022-01-10 2023-07-25 安徽贝克生物制药有限公司 一种阿巴卡韦、拉米夫定、依非韦伦复方片及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01501934A (ja) 1986-04-01 1989-07-06 ジ・アップジョン・カンパニー メチルプレドニソロン／カルボキシメチルスターチナトリウム錠剤組成物
NZ231246A (en) * 1989-04-28 1997-06-24 Daiichi Seiyaku Co Pharmaceutical compositions comprising fluorine containing pyridone-carboxylic acid derivatives
SG49770A1 (en) * 1992-07-08 1998-06-15 Santen Oy Pharmaceutical preparation
US5665720A (en) 1992-08-07 1997-09-09 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
US5455045A (en) * 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
WO1995020389A1 (en) * 1994-01-28 1995-08-03 Merck & Co., Inc. Benzoxazinones as inhibitors of hiv reverse transcriptase
US5663467A (en) * 1995-01-23 1997-09-02 Merck & Co., Inc. Synthesis of cyclopropylacetylene
IT1281502B1 (it) * 1995-06-13 1998-02-18 Sardinian Antiviral Research C Impiego di un inibitore non nucleosidico della trascrittasi inversa in associazione con inibitori nucleosidici per il trattamento della
UA72207C2 (uk) * 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення
CO5070643A1 (es) 1998-05-27 2001-08-28 Merck & Co Inc Formulacion en tabletas comprimidas

Also Published As

Publication number Publication date
NO20005043L (no) 2000-10-06
PL194309B1 (pl) 2007-05-31
AU756422B2 (en) 2003-01-09
EE200000589A (et) 2002-04-15
KR100634253B1 (ko) 2006-10-16
US6238695B1 (en) 2001-05-29
EP1067936A1 (en) 2001-01-17
ZA200004313B (en) 2002-01-30
ATE223719T1 (de) 2002-09-15
AR019031A1 (es) 2001-12-26
NO325824B1 (no) 2008-07-21
DE69902893D1 (de) 2002-10-17
BR9908810A (pt) 2000-12-19
JP2002510634A (ja) 2002-04-09
CN1146419C (zh) 2004-04-21
EP1067936B1 (en) 2002-09-11
US6555133B2 (en) 2003-04-29
TW576741B (en) 2004-02-21
NO20005043D0 (no) 2000-10-06
IL138078A0 (en) 2001-10-31
CZ300850B6 (cs) 2009-08-26
SK284655B6 (sk) 2005-08-04
ES2181417T3 (es) 2003-02-16
DK1067936T3 (da) 2003-02-17
US20010012518A1 (en) 2001-08-09
HUP0101517A2 (hu) 2001-11-28
CA2321523A1 (en) 1999-10-14
KR20010042473A (ko) 2001-05-25
NZ507566A (en) 2002-11-26
WO1999051239A1 (en) 1999-10-14
CZ20003571A3 (cs) 2001-01-17
UA72207C2 (uk) 2005-02-15
SK14612000A3 (sk) 2001-07-10
EA200001030A1 (ru) 2001-04-23
EA003217B1 (ru) 2003-02-27
HU228498B1 (en) 2013-03-28
HUP0101517A3 (en) 2002-11-28
CA2321523C (en) 2008-10-07
IL138078A (en) 2005-12-18
DE69902893T2 (de) 2003-04-30
CN1296412A (zh) 2001-05-23
AU3463799A (en) 1999-10-25
PT1067936E (pt) 2002-12-31
PL343421A1 (en) 2001-08-13

Similar Documents

Publication Publication Date Title
EE04391B1 (et) Kiirlahustuvate efavirenskapslite või -tablettideformulatsioonid, kasutades superlagundeid, ning nende valmistamise meetodid
NO996433L (no) Nye formuleringer av legemidler, fremgangsmåter for fremstilling derav og fremgangsmåter for anvendelse derav
IS5747A (is) Oxazólidínón afleiður, aðferð fyrir framleiðslu þeirra og lyfjasamsetninga sem innihalda þær
NO20001409L (no) Karboksamidotiazolderivater, fremgangsmÕte for fremstilling derav og farmasøytiske blandinger
HUP0103913A3 (en) Novel form of irbesartan, methods for obtaining said form and pharmaceutical compositions containing same
NO20004643D0 (no) Polymerbaserte raskt oppløselige tabletter og fremgangsmÕte for fremstilling derav
DK1112266T3 (da) Substituerede 4-amino-2-arylpyrimidiner, fremstilling og anvendelse deraf og farmaceutiske præparater indeholdende dem
NO20032332L (no) Benzodiazepinderivatforbindelser, fremgangsmåte til fremstilling og anvendelse derav
IS2821B (is) Amínóalkýlbensóýl-bensófúran eða bensóþíófenafleiður, aðferð til framleiðslu þeirra og samsetningar sem innihalda þær
NO20012963L (no) Fremgangsmåte for fremstilling av 3-alkanoylindoler og 3- alkylindoler
NO20015659L (no) Purinderivater, fremstillingsmetode og farmasöytiske preparater inneholdende disse
DK1131052T3 (da) Vaginalt indgivelige progesteron-holdige tabletter og fremgangsmåde til fremstilling deraf
PL350902A1 (en) Pyridothiene diazepins, method of obtaining them and pharmacological compositions containing them
HUP0100342A3 (en) Novel acronycine derivatives, preparation method and pharmaceutical compositions
PL342453A1 (en) Biphenylsulphonylcyanamides, method of obtaining them and their application as drugs
HK1047407A1 (en) Polymorphs of n-methyl-n-(3-Ä2-thienylcarbonylÜ-pyrazol-Ä1,5-alphaÜ-pyrimidin-7-ylÜphenyl)acetamide and compositions and methods related thereto.
EP1329516A4 (en) METHOD FOR SCREENING A PHYSIOLOGICALLY ACTIVE SUBSTANCE
ZA99168B (en) Pharmaceutical formulations and processes for their preparation.
DK1076651T3 (da) Substituerede sulfonylcyanamider, fremgangsmåde til fremstilling heraf og anvendelsen heraf som lægemidler
SI1067936T1 (en) Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants
DK1259523T3 (da) Pluraflaviner og derivater deraf, fremgangsmåde til fremstilling og anvendelse deraf
PL332894A1 (en) Hadgehog protein conjugate, method of obtaining same, pharmaceutic composition and method of obtaining same, hedgehog protein
EE200100474A (et) Antratsükliinide L-arabinodisahhariidid, nende valmistamise meetodid ning neid sisaldavad ravimkoostised
DK1047668T3 (da) Triazepinoner, fremgangsmåde til fremstilling deraf og terapeutisk anvendelse deraf
DZ3065A1 (fr) Formulations pour la toux à base de plantes médicinales et procédés pour leur préparation.

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231